search button

GEFT protein expression in digestive tract malignant tumors and its clinical significance

  • Authors:
    • Yuanyuan Wang
    • Bing Zhang
    • Ge Gao
    • Yinping Zhang
    • Qingxin Xia

  • View Affiliations

  • Published online on: September 24, 2019     https://doi.org/10.3892/ol.2019.10915
  • Pages: 5577-5590
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Guanine nucleotide exchange factor T (GEFT), a member of the Rho guanine nucleotide exchange factor family, is expressed in a variety of tumors. In the present study, the expression and clinical significance of GEFT in malignant digestive tract tumors was assessed. Tumor and adjacent control samples from 180 patients were tested. Positive GEFT expression rates were 80, 83.33 and 86.67% in esophageal squamous carcinoma (ESCC), gastric carcinoma (GC) and colorectal cancer (CRC), respectively. GEFT expression was associated with diffuse type carcinoma according to the Lauren classification (χ2=12.525, P=0.002) and tumor‑node‑metastasis (TNM) stages III/IV (χ2=4.033, P=0.045) in GC, and with vessel carcinoma embolus (χ2=7.890, P=0.005) and lymph node metastasis (χ2=5.455, P=0.020) in CRC, but was not associated with other clinicopathological parameters. Patients with high levels of GEFT protein expression had a less favorable outcome compared with patients with low levels of GEFT expression in patients with CRC (χ2=3.876, P=0.049). However, a significant association was not found between GEFT expression and overall survival in patients with ESCC (χ2=0.040, P=0.842) or GC (χ2=0.501, P=0.479). The rate of human epidermal growth factor receptor 2 upregulation in patients with GC was 13.33% and it was associated with nerve invasion (χ2=4.005, P=0.045) and TNM stages III/IV (χ2=5.600, P=0.018). Mismatch repair protein (MMRP) defect was observed in six cases, and the KRAS mutation rate was 26.67% in patients with CRC. GEFT expression was significantly correlated with MMRP (r=‑0.285, P=0.027) and KRAS mutation in patients with CRC (r=0.697, P<0.001). These findings revealed frequent GEFT upregulation in malignant digestive tract tumors, which may have promoted tumor development. GEFT expression in CRC may be associated with microsatellite instability and KRAS mutation status, suggesting that GEFT may be a potential therapeutic target for patients with CRC.
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 18 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Zhang B, Gao G, Zhang Y and Xia Q: GEFT protein expression in digestive tract malignant tumors and its clinical significance. Oncol Lett 18: 5577-5590, 2019
APA
Wang, Y., Zhang, B., Gao, G., Zhang, Y., & Xia, Q. (2019). GEFT protein expression in digestive tract malignant tumors and its clinical significance. Oncology Letters, 18, 5577-5590. https://doi.org/10.3892/ol.2019.10915
MLA
Wang, Y., Zhang, B., Gao, G., Zhang, Y., Xia, Q."GEFT protein expression in digestive tract malignant tumors and its clinical significance". Oncology Letters 18.5 (2019): 5577-5590.
Chicago
Wang, Y., Zhang, B., Gao, G., Zhang, Y., Xia, Q."GEFT protein expression in digestive tract malignant tumors and its clinical significance". Oncology Letters 18, no. 5 (2019): 5577-5590. https://doi.org/10.3892/ol.2019.10915